Last reviewed 2026-04-22 · How we verify

ABT-450/r/ABT-267

ABT-450/r/ABT-267 is a Hepatitis C virus protease inhibitor and NS5A inhibitor combination Small molecule drug developed by AbbVie. It is currently in Phase 3 development for Chronic hepatitis C virus infection (genotype 1). Also known as: ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, Paritaprevir/ritonavir/ombitasvir also known as Viekirax, ombitasvir/paritaprevir/ritonavir.

ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication.

ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication. Used for Chronic hepatitis C virus infection (genotype 1).

At a glance

Mechanism of action

ABT-450 inhibits the hepatitis C virus NS3/4A serine protease, which is essential for viral polyprotein processing and replication. ABT-267 targets the NS5A protein, which is critical for viral RNA replication and assembly. The ritonavir boosts ABT-450 levels by inhibiting its metabolism, allowing for lower and less frequent dosing while maintaining therapeutic concentrations.

Approved indications

• Chronic hepatitis C virus infection (genotype 1)

Common side effects

• Headache
• Fatigue
• Nausea
• Diarrhea
• Elevated bilirubin

Key clinical trials

• MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
• Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (PHASE2)
• A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (PHASE3)
• Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt (PHASE3)
• A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PHASE2)
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ABT-450/r/ABT-267 CI brief — competitive landscape report
• ABT-450/r/ABT-267 updates RSS · CI watch RSS
• AbbVie portfolio CI

Frequently asked questions about ABT-450/r/ABT-267

Related

• Drug class: All Hepatitis C virus protease inhibitor and NS5A inhibitor combination drugs
• Target: All drugs targeting HCV NS3/4A protease and NS5A protein
• Manufacturer: AbbVie — full pipeline
• Therapeutic area: All drugs in Virology/Hepatology
• Indication: Drugs for Chronic hepatitis C virus infection (genotype 1)
• Also known as: ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, Paritaprevir/ritonavir/ombitasvir also known as Viekirax, ombitasvir/paritaprevir/ritonavir, ombitasvir also known as ABT-267